Loading company…
Founded in 2013 and based in London, NightstaRx Limited develops gene therapies for inherited retinal diseases.
Founded in 2013 and based in London, UK, NightstaRx Limited develops gene therapies for inherited retinal diseases, including choroideremia, X-linked retinitis pigmentosa and best vitelliform macular dystrophy. The company is listed at the Series C stage.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in